09:57 AM EST - Oncolytics Biotech Inc : Announces it has received written feedback from the U.S. Food and Drug Administration regarding the design of a potential pivotal Part B expansion of REO 033, the Company’s ongoing randomized study evaluating pelareorep in second-line RAS-mutant, microsatellite stable metastatic colorectal cancer. Oncolytics Biotech Inc
shares N.ONCY are trading up one cent at $0.83.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONCY&qmodStoryID=4568478878479694
